{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:09:32Z","timestamp":1791284972636,"version":"4.1.0"},"reference-count":41,"publisher":"The Endocrine Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,9,1]]},"abstract":"<jats:p>Androgen deprivation, a consequence of hypogonadism, certain cancer treatments, or normal aging in men, leads to loss of muscle mass, increased adiposity, and osteoporosis. In the present study, using a soluble chimeric form of activin receptor type IIB (ActRIIB) we sought to offset the adverse effects of androgen deprivation on muscle, adipose tissue, and bone. Castrated (ORX) or sham-operated (SHAM) mice received either TBS [vehicle-treated (VEH)] or systemic administration of ActRIIB-mFc, a soluble fusion protein comprised of a form of the extracellular domain of ActRIIB fused to a murine IgG2aFc subunit. In vivo body composition imaging demonstrated that ActRIIB-mFc treatment results in increased lean tissue mass of 23% in SHAM mice [19.02 \u00b1 0.42 g (VEH) versus 23.43 \u00b1 0.35 g (ActRIIB-mFc), P &amp;lt; 0.00001] and 26% in ORX mice [15.59 \u00b1 0.26 g (VEH) versus 19.78 \u00b1 0.26 g (ActRIIB-mFc), P &amp;lt; 0.00001]. Treatment also caused a decrease in adiposity of 30% in SHAM mice [5.03 \u00b1 0.48 g (VEH) versus 3.53 \u00b1 0.19 g (ActRIIB-mFc), NS] and 36% in ORX mice [7.12 \u00b1 0.53 g (VEH) versus 4.57 \u00b1 0.28 g (ActRIIB-mFc), P &amp;lt; 0.001]. These changes were also accompanied by altered serum levels of leptin, adiponectin, and insulin, as well as by prevention of steatosis (fatty liver) in ActRIIB-mFc-treated ORX mice. Finally, ActRIIB-mFc prevented loss of bone mass in ORX mice as assessed by whole body dual x-ray absorptiometry and micro-computed tomography of proximal tibias. The data demonstrate that treatment with ActRIIB-mFc restored muscle mass, adiposity, and bone quality to normal levels in a mouse model of androgen deprivation, thereby alleviating multiple adverse consequences of such therapy.<\/jats:p>","DOI":"10.1210\/en.2010-0134","type":"journal-article","created":{"date-parts":[[2010,6,24]],"date-time":"2010-06-24T01:10:13Z","timestamp":1277341813000},"page":"4289-4300","source":"Crossref","is-referenced-by-count":68,"title":["A Soluble Activin Receptor Type IIB Prevents the Effects of Androgen Deprivation on Body Composition and Bone Health"],"prefix":"10.1210","volume":"151","author":[{"given":"Alan","family":"Koncarevic","sequence":"first","affiliation":[{"name":"Acceleron Pharma, Inc., Cambridge, Massachusetts 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton","family":"Cornwall-Brady","sequence":"additional","affiliation":[{"name":"Acceleron Pharma, Inc., Cambridge, Massachusetts 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Pullen","sequence":"additional","affiliation":[{"name":"Acceleron Pharma, Inc., Cambridge, Massachusetts 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Davies","sequence":"additional","affiliation":[{"name":"Acceleron Pharma, Inc., Cambridge, Massachusetts 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianne","family":"Sako","sequence":"additional","affiliation":[{"name":"Acceleron Pharma, Inc., Cambridge, Massachusetts 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June","family":"Liu","sequence":"additional","affiliation":[{"name":"Acceleron Pharma, Inc., Cambridge, Massachusetts 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra","family":"Kumar","sequence":"additional","affiliation":[{"name":"Acceleron Pharma, Inc., Cambridge, Massachusetts 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Tomkinson","sequence":"additional","affiliation":[{"name":"Acceleron Pharma, Inc., Cambridge, Massachusetts 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Baker","sequence":"additional","affiliation":[{"name":"Acceleron Pharma, Inc., Cambridge, Massachusetts 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Umiker","sequence":"additional","affiliation":[{"name":"Acceleron Pharma, Inc., Cambridge, Massachusetts 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Monnell","sequence":"additional","affiliation":[{"name":"Acceleron Pharma, Inc., Cambridge, Massachusetts 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asya V.","family":"Grinberg","sequence":"additional","affiliation":[{"name":"Acceleron Pharma, Inc., Cambridge, Massachusetts 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Liharska","sequence":"additional","affiliation":[{"name":"Acceleron Pharma, Inc., Cambridge, Massachusetts 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn W.","family":"Underwood","sequence":"additional","affiliation":[{"name":"Acceleron Pharma, Inc., Cambridge, Massachusetts 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Ucran","sequence":"additional","affiliation":[{"name":"Acceleron Pharma, Inc., Cambridge, Massachusetts 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Howard","sequence":"additional","affiliation":[{"name":"Acceleron Pharma, Inc., Cambridge, Massachusetts 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Barberio","sequence":"additional","affiliation":[{"name":"Acceleron Pharma, Inc., Cambridge, Massachusetts 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Spaits","sequence":"additional","affiliation":[{"name":"Acceleron Pharma, Inc., Cambridge, Massachusetts 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Pearsall","sequence":"additional","affiliation":[{"name":"Acceleron Pharma, Inc., Cambridge, Massachusetts 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasbir","family":"Seehra","sequence":"additional","affiliation":[{"name":"Acceleron Pharma, Inc., Cambridge, Massachusetts 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Lachey","sequence":"additional","affiliation":[{"name":"Acceleron Pharma, Inc., Cambridge, Massachusetts 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2010,7,23]]},"reference":[{"key":"2020071614210124100_R1","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1210\/jc.2006-1859","article-title":"The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men.","volume":"92","author":"Travison","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614210124100_R2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/ncpendmet1050","article-title":"Testosterone and ill-health in aging men.","volume":"5","author":"Yeap","year":"2009","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"2020071614210124100_R3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1517\/14656566.6.1.45","article-title":"Pharmacotherapy of osteoporosis in men.","volume":"6","author":"Diamond","year":"2005","journal-title":"Expert Opin Pharmacother"},{"key":"2020071614210124100_R4","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/jnci\/djn389","article-title":"Annual report to the nation on the status of cancer, 1975\u20132005, featuring trends in lung cancer, tobacco use, and tobacco control.","volume":"100","author":"Jemal","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"2020071614210124100_R5","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen deprivation therapy for prostate cancer.","volume":"294","author":"Sharifi","year":"2005","journal-title":"JAMA"},{"key":"2020071614210124100_R6","first-page":"317","article-title":"The cost of treating skeletal-related events in patients with prostate cancer.","volume":"14","author":"Lage","year":"2008","journal-title":"Am J Manag Care"},{"key":"2020071614210124100_R7","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3322\/CA.2008.0002","article-title":"Management of complications of prostate cancer treatment.","volume":"58","author":"Michaelson","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"2020071614210124100_R8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0022-5347(01)65165-6","article-title":"Osteoporosis after orchiectomy for prostate cancer.","volume":"157","author":"Daniell","year":"1997","journal-title":"J Urol"},{"key":"2020071614210124100_R9","doi-asserted-by":"crossref","first-page":"18117","DOI":"10.1073\/pnas.0505996102","article-title":"Regulation of muscle growth by multiple ligands signaling through activin type II receptors.","volume":"102","author":"Lee","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071614210124100_R10","article-title":"13 May 2010 Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type.","author":"Cadena","journal-title":"J Appl Physiol 10.1152\/japplphysiol.00866.2009"},{"key":"2020071614210124100_R11","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.expneurol.2009.02.017","article-title":"A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis.","volume":"217","author":"Morrison","year":"2009","journal-title":"Exp Neurol"},{"key":"2020071614210124100_R12","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1471-213X-9-24","article-title":"Redundancy of myostatin and growth\/differentiation factor 11 function.","volume":"9","author":"McPherron","year":"2009","journal-title":"BMC Dev Biol"},{"key":"2020071614210124100_R13","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1172\/JCI0213562","article-title":"Suppression of body fat accumulation in myostatin-deficient mice.","volume":"109","author":"McPherron","year":"2002","journal-title":"J Clin Invest"},{"key":"2020071614210124100_R14","doi-asserted-by":"crossref","first-page":"E506","DOI":"10.1152\/ajpendo.00058.2006","article-title":"Continuous testosterone administration prevents skeletal muscle atrophy and enhances resistance to fatigue in orchidectomized male mice","volume":"291","author":"Axell","year":"2006","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2020071614210124100_R15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1017\/S0016672397002905","article-title":"The effect of testosterone in mice divergently selected on fat content or body weight.","volume":"70","author":"Hastings","year":"1997","journal-title":"Genet Res"},{"key":"2020071614210124100_R16","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1210\/er.2003-0003","article-title":"Androgens and bone.","volume":"25","author":"Vanderschueren","year":"2004","journal-title":"Endocr Rev"},{"key":"2020071614210124100_R17","doi-asserted-by":"crossref","first-page":"14938","DOI":"10.1073\/pnas.95.25.14938","article-title":"Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting.","volume":"95","author":"Gonzalez-Cadavid","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071614210124100_R18","first-page":"343","article-title":"Serum myostatin-immunoreactive protein is increased in 60\u201392 year old women and men with muscle wasting.","volume":"6","author":"Yarasheski","year":"2002","journal-title":"J Nutr Health Aging"},{"key":"2020071614210124100_R19","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1210\/en.2006-1500","article-title":"Ectopic expression of myostatin induces atrophy of adult skeletal muscle by decreasing muscle gene expression.","volume":"148","author":"Durieux","year":"2007","journal-title":"Endocrinology"},{"key":"2020071614210124100_R20","doi-asserted-by":"crossref","first-page":"E876","DOI":"10.1152\/ajpendo.00107.2003","article-title":"Lower skeletal muscle mass in male transgenic mice with muscle-specific overexpression of myostatin","volume":"285","author":"Reisz-Porszasz","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2020071614210124100_R21","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1126\/science.1069525","article-title":"Induction of cachexia in mice by systemically administered myostatin.","volume":"296","author":"Zimmers","year":"2002","journal-title":"Science"},{"key":"2020071614210124100_R22","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nature01154","article-title":"Functional improvement of dystrophic muscle by myostatin blockade.","volume":"420","author":"Bogdanovich","year":"2002","journal-title":"Nature"},{"key":"2020071614210124100_R23","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/mus.20920","article-title":"Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C.","volume":"37","author":"Bogdanovich","year":"2008","journal-title":"Muscle Nerve"},{"key":"2020071614210124100_R24","doi-asserted-by":"crossref","first-page":"12457","DOI":"10.1073\/pnas.94.23.12457","article-title":"Double muscling in cattle due to mutations in the myostatin gene.","volume":"94","author":"McPherron","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071614210124100_R25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/387083a0","article-title":"Regulation of skeletal muscle mass in mice by a new TGF-\u03b2 superfamily member.","volume":"387","author":"McPherron","year":"1997","journal-title":"Nature"},{"key":"2020071614210124100_R26","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1371\/journal.pgen.0030079","article-title":"A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs","volume":"3","author":"Mosher","year":"2007","journal-title":"PLoS Genet"},{"key":"2020071614210124100_R27","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.bbrc.2009.03.014","article-title":"ALK7 expression is specific for adipose tissue, reduced in obesity and correlates to factors implicated in metabolic disease.","volume":"382","author":"Carlsson","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"2020071614210124100_R28","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1210\/en.2005-0362","article-title":"Myostatin inhibits myogenesis and promotes adipogenesis in C3H 10T(1\/2) mesenchymal multipotent cells.","volume":"146","author":"Artaza","year":"2005","journal-title":"Endocrinology"},{"key":"2020071614210124100_R29","doi-asserted-by":"crossref","first-page":"e4937","DOI":"10.1371\/journal.pone.0004937","article-title":"Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improves insulin sensitivity","volume":"4","author":"Guo","year":"2009","journal-title":"PLoS One"},{"key":"2020071614210124100_R30","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1038\/ijo.2009.162","article-title":"The effects of a soluble activin type IIB receptor on obesity and insulin sensitivity.","volume":"33","author":"Akpan","year":"2009","journal-title":"Int J Obes (Lond)"},{"key":"2020071614210124100_R31","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/HYPERTENSIONAHA.107.099424","article-title":"Adiponectin, cardiovascular function, and hypertension.","volume":"51","author":"Wang","year":"2008","journal-title":"Hypertension"},{"key":"2020071614210124100_R32","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.2337\/diabetes.51.9.2734","article-title":"Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein.","volume":"51","author":"Nishizawa","year":"2002","journal-title":"Diabetes"},{"key":"2020071614210124100_R33","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1210\/jcem.82.8.4174","article-title":"Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men.","volume":"82","author":"Jockenho\u0308vel","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614210124100_R34","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s00223-001-2037-3","article-title":"Activin A increases the bone mass of grafted bone in C3H\/HeJ mice.","volume":"70","author":"Hirotani","year":"2002","journal-title":"Calcif Tissue Int"},{"key":"2020071614210124100_R35","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1471-2474-7-62","article-title":"Simultaneous gene transfer of bone morphogenetic protein (BMP) -2 and BMP-7 by in vivo electroporation induces rapid bone formation and BMP-4 expression.","volume":"7","author":"Kawai","year":"2006","journal-title":"BMC Musculoskelet Disord"},{"key":"2020071614210124100_R36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00113-009-1673-3","article-title":"[Therapy-resistant tibial pseudarthrosis: treatment success with BMP-7 combined with autologous bone.].","volume":"113","author":"Siebenlist","year":"2010","journal-title":"Unfallchirurg"},{"key":"2020071614210124100_R37","article-title":"12 April 2010 Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIB.","author":"Sako","journal-title":"J Biol Chem 10.1074\/jbc.M110.114959"},{"key":"2020071614210124100_R38","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00427-007-0162-3","article-title":"Characterization of amphioxus GDF8\/11 gene, an archetype of vertebrate MSTN and GDF11.","volume":"217","author":"Xing","year":"2007","journal-title":"Dev Genes Evol"},{"key":"2020071614210124100_R39","doi-asserted-by":"crossref","first-page":"7082","DOI":"10.1073\/pnas.0711263105","article-title":"A soluble activin type IIA receptor induces bone formation and improves skeletal integrity.","volume":"105","author":"Pearsall","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071614210124100_R40","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.bone.2009.09.018","article-title":"Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis).","volume":"46","author":"Fajardo","year":"2010","journal-title":"Bone"},{"key":"2020071614210124100_R41","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.bone.2010.01.370","article-title":"A soluble activin receptor type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in cynomolgus monkeys.","volume":"46","author":"Lotinun","year":"2010","journal-title":"Bone"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/151\/9\/4289\/9011792\/endo4289.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/151\/9\/4289\/9011792\/endo4289.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T02:02:21Z","timestamp":1594951341000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/151\/9\/4289\/2456897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,23]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9,1]]}},"URL":"https:\/\/doi.org\/10.1210\/en.2010-0134","relation":{},"ISSN":["0013-7227","1945-7170"],"issn-type":[{"value":"0013-7227","type":"print"},{"value":"1945-7170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,23]]}}}